Aventiv Research, Inc — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$4,744	2
2022	Research	$235,479	22
2021	Research	$109,489	23
2020	Research	$153,680	187

Breakdown

Who paid Research payments · program years 2020–2023

Emergent BioSolutions Inc. $240,832 23 payments
Novo Nordisk AS $163,503 203 payments
AstraZeneca Pharmaceuticals LP $90,996 5 payments
Exeltis, USA Inc. $5,061 2 payments
Chugai Pharmaceutical Co., Ltd. $3,000 1 payment

Studies the money was for Research payments · program years 2020–2023

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $232,479 21 payments
Nn9536-4451 $76,368 201 payments
Nn8022-4180 $68,294 1 payment
AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $48,073 2 payments
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $39,127 2 payments
Cor-001-02 $18,842 1 payment
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents $7,500 1 payment
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $3,891 1 payment
A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate to severe Asthma $3,796 1 payment
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Biomarkers of Donq52 in Celiac Disease Patients $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.